Shah Sachin R
Associate Professor of Pharmacy Practice/Hematology-Oncology Clinical Pharmacist Texas Tech University Health Sciences Center, School of Pharmacy/Veterans Affairs North Texas Healthcare System, Dallas, TX 75216, USA.
Expert Opin Biol Ther. 2008 Jun;8(6):799-804. doi: 10.1517/14712598.8.6.799.
Even though all immunoglobulin intravenous (IGIV) end products have high IgG concentrations, variations in manufacturing processes lead to unique product characteristics.
Solvent/detergent-treated IGIV (IGIV-S/D) liquid 10% (Gammagard or Kiovig liquid) is one of the newer products, and this article will discuss and compare its efficacy, safety, tolerability and effect on patient care.
The search terms 'immunoglobulin,' 'IGIV,' 'IVIG,' and 'liquid' were entered into PubMed/Medline and Google for the literature search in preparation of this manuscript. Additional references were screened from researched literature.
RESULTS/CONCLUSION: Gammagard liquid 10% has shown significant activity in primary immunodeficiency and immune thrombocytopenic purpura. It is a sugar- and sodium-free product with improved safety, tolerability and convenience. Overall, Gammagard liquid is a valuable addition to available therapies that has utility in life-threatening and complicated diseases, and its use will continue to grow.
尽管所有静脉注射免疫球蛋白（IGIV）终产品都有高浓度的IgG，但生产工艺的差异导致了产品的独特特性。
溶剂/去污剂处理的10%液体IGIV（IGIV-S/D，即Gammagard或Kiovig液体）是较新的产品之一，本文将讨论并比较其疗效、安全性、耐受性以及对患者护理的影响。
在准备本手稿时，将检索词“免疫球蛋白”“IGIV”“IVIG”和“液体”输入PubMed/Medline和谷歌进行文献检索。从检索到的文献中筛选其他参考文献。
结果/结论：10%的Gammagard液体在原发性免疫缺陷和免疫性血小板减少性紫癜中显示出显著活性。它是一种无糖无钠产品，安全性、耐受性和便利性有所提高。总体而言，Gammagard液体是现有治疗方法中的一项有价值的补充，可用于治疗危及生命和复杂的疾病，其应用将持续增加。
